Plasma pTau217/Abeta42 Ratio Outperforms Individual Biomarkers for Detecting Brain Amyloidosis
In a multicenter study of 423 participants with cognitive complaints (validated in 1,176 ADNI subjects), the plasma pTau217/Abeta42 ratio achieved an AUC of 0.927 for detecting amyloid-positive status, outperforming pTau217 alone. Crucially, a two-cutoff workflow using the ratio reduced the diagnostically ambiguous intermediate-risk zone from 16% to 8%, improving clinical decision-making. The ratio also mitigated confounding effects of renal function, supporting its robustness across patient populations.
The original study
Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis.
- Authors
- Lehmann S, Gabelle A, Duchiron M, Busto G, Morchikh M, Delaby C, et al.
- Journal
- EBioMedicine
- Type
- Clinical Trial, Comparative Study, Journal Article, Multicenter Study
- PMID
- 40513421
Original abstract
BACKGROUND: Early detection of brain amyloidosis (Aβ+) is crucial for diagnosing Alzheimer' disease (AD) and optimizing patient management, especially in light of emerging treatments. While plasma biomarkers are promising, their combined diagnostic value through specific ratios remains underexplored. In this study, we assess the diagnostic accuracy of plasma pTau isoform (pTau181 and pTau217) to Aβ42 ratios in detecting Aβ+ status. METHODS: This study included 423 participants from the multicenter prospective ALZAN cohort, recruited for cognitive complaints. Aβ+ status was determined using cerebrospinal fluid (CSF) biomarkers. The confirmatory cohort comprises 1176 patient samples from the Alzheimer's Disease Neuroimaging Initiative (ADNI), with Aβ+ status determined by positron emission tomography (PET) imaging. Plasma biomarkers (pTau181, pTau217, Aβ40, Aβ42) were measured using immunoassays and mass spectrometry, with specific ratios calculated. In the ALZAN cohort, the impact of confounding factors such as age, renal function, ApoE 4 status, body mass index, and the delay between blood collection and processing was also evaluated to assess their influence on biomarker concentrations and diagnostic performance. The primary outcome was the diagnostic performance of plasma biomarkers and their ratios for detecting Aβ+ status. Secondary outcomes in the ALZAN cohort included the proportion of patients classified as low, intermediate, or high risk for Aβ+ using a two-cutoff approach. FINDINGS: In ALZAN the pTau181/Aβ42 ratio matched the diagnostic performance of pTau217 (AUC of 0.911 (0.882-0.940) vs. 0.909 (0.879-0.939), P = 0.85). The pTau217/Aβ42 ratio demonstrated the highest diagnostic accuracy, with an AUC of 0.927 (0.900-0.954). Both ratios effectively mitigated confounding factors, such as variations in renal function, and were also efficient in identifying Aβ+ status in individuals with early cognitive decline. Diagnostic accuracy of ratios vs. individual measurement was confirmed in the ADNI cohort. In ALZAN, using two-cutoff workflows with pTau217/Aβ42 instead of pTau217 alone reduced the intermediate-risk zone from ∼16% to ∼8%, enhancing stratification for clinical decision-making. INTERPRETATION: The pTau217/Aβ42 ratio demonstrated improved diagnostic performance for detecting Aβ+ compared to individual biomarkers, potentially reducing diagnostic uncertainty. These findings suggest that plasma biomarker ratios could be useful; however, further validation in independent and diverse clinical settings is necessary before broader clinical implementation. FUNDING: Fondation Research Alzheimer (ALZAN projet), AXA Mécénat Santé (INTERVAL Project), Fondation pour la Recherche Médicale (FRM, team Proteinopathies).